stockrow
Saturday 7 November 2026
Export SPTX’s income statement to Excel — free account
Seaport Therapeutics, Inc
SPTX Healthcare Biotechnology
- EPS
- +94.8%
- Free cash flow
- −43.8%
Quarter to September 2026, against a year earlier
21.18
0.79
+3.87%
Follow SPTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (47) | (74) | (137) | +58.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (47) | (75) | (139) | +59.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (49.72) | (31.54) | (22.68) | (36.6%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (31.42) | (32.83) | (1.79) | +4.5% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.12) | (0.15) | 0.00 | +25.2% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (31.54) | (32.98) | (1.79) | +4.6% | ||||||
| Book value | — | — | — | — | — | — | — | — | (26.35) | 98.06 | 7.42 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 2 | 23 | +151.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (30) | (78) | (96) | +163.1% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | +215.0% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (30) | (78) | (96) | +163.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 299 | 210 | 282 | (29.6%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (309) | (216) | (290) | (30.0%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (25) | 233 | 397 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (26.52) | (37.78) | (26.5) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (324.62) | (88.12) | (324.6) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 127.57 | (74.36) | +127.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 58 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 5 Nov 2026
Seaport Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| RAPP Rapport Therapeutics, Inc. | $1.1B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGP SpyGlass Pharma, Inc. | $1.1B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| SPTX Seaport Therapeutics, Inc | $1.1B | — (loss-making) | — | — | n/m | −43.81% (below 0%: shrinking) | — | 0.00% | |
| JANX Janux Therapeutics, Inc. | $981.9M | — (loss-making) | — (loss-making) | 0.00% | n/m | −94.49% (below 0%: shrinking) | 100.00% | (336.51%) | Compare |
| Median of peers | $1.1B | — | — | +68.81% | — | −64.75% | 50.00% | 0.00% |